SIRPA and neoplasm: Turning off this signaling by knocking out the SIRP-α using CRISPR/Cas9 enables phagocytosis of cancer cells (108); (II) Kindlin2, this protein is another therapeutic target that increases the secretion of Cancer Stimulating Factor1 (CSF1) from tumor cells.